Targeted Therapy of Acute Myeloid Leukemia:
This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapter...
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer New York
2015
|
| Ausgabe: | 1st ed. 2015 |
| Schriftenreihe: | Current Cancer Research
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. |
| Beschreibung: | Introduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- - The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXR Part: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cell's Consequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- - Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies |
| Beschreibung: | 1 Online Ressource (XIX, 826 Seiten, 62 Illustrationen, 46 Illustrationen in Farbe) |
| ISBN: | 9781493913930 |
| DOI: | 10.1007/978-1-4939-1393-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046814959 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200720s2015 |||| o||u| ||||||eng d | ||
| 020 | |a 9781493913930 |9 978-1-4939-1393-0 | ||
| 024 | 7 | |a 10.1007/978-1-4939-1393-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4939-1393-0 | ||
| 035 | |a (OCoLC)1190928949 | ||
| 035 | |a (DE-599)BVBBV046814959 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 614.5999 | |
| 245 | 1 | 0 | |a Targeted Therapy of Acute Myeloid Leukemia |c edited by Michael Andreeff |
| 250 | |a 1st ed. 2015 | ||
| 264 | 1 | |a New York, NY |b Springer New York |c 2015 | |
| 300 | |a 1 Online Ressource (XIX, 826 Seiten, 62 Illustrationen, 46 Illustrationen in Farbe) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Current Cancer Research | |
| 500 | |a Introduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- | ||
| 500 | |a - The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXR Part: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cell's Consequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- | ||
| 500 | |a - Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies | ||
| 520 | |a This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. | ||
| 650 | 4 | |a Cancer research | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Cell biology | |
| 650 | 4 | |a Microbiology | |
| 700 | 1 | |a Andreeff, Michael |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493913923 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493913947 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493939893 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4939-1393-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_2015 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032223440 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4939-1393-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_2015 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804181623467409408 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| building | Verbundindex |
| bvnumber | BV046814959 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4939-1393-0 (OCoLC)1190928949 (DE-599)BVBBV046814959 |
| dewey-full | 614.5999 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 614 - Forensic medicine; incidence of disease |
| dewey-raw | 614.5999 |
| dewey-search | 614.5999 |
| dewey-sort | 3614.5999 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-1-4939-1393-0 |
| edition | 1st ed. 2015 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05213nmm a2200493zc 4500</leader><controlfield tag="001">BV046814959</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200720s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781493913930</subfield><subfield code="9">978-1-4939-1393-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4939-1393-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4939-1393-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1190928949</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046814959</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">614.5999</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted Therapy of Acute Myeloid Leukemia</subfield><subfield code="c">edited by Michael Andreeff</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online Ressource (XIX, 826 Seiten, 62 Illustrationen, 46 Illustrationen in Farbe)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Current Cancer Research</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Introduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXR Part: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cell's Consequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cell biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Andreeff, Michael</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493913923</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493913947</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493939893</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4939-1393-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2015</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032223440</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-1393-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_2015</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046814959 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:00:00Z |
| indexdate | 2024-07-10T08:54:36Z |
| institution | BVB |
| isbn | 9781493913930 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032223440 |
| oclc_num | 1190928949 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online Ressource (XIX, 826 Seiten, 62 Illustrationen, 46 Illustrationen in Farbe) |
| psigel | ZDB-2-SME ZDB-2-SME_2015 ZDB-2-SME ZDB-2-SME_2015 |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Springer New York |
| record_format | marc |
| series2 | Current Cancer Research |
| spelling | Targeted Therapy of Acute Myeloid Leukemia edited by Michael Andreeff 1st ed. 2015 New York, NY Springer New York 2015 1 Online Ressource (XIX, 826 Seiten, 62 Illustrationen, 46 Illustrationen in Farbe) txt rdacontent c rdamedia cr rdacarrier Current Cancer Research Introduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- - The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXR Part: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RARα with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cell's Consequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- - Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. Cancer research Pharmacology Cell biology Microbiology Andreeff, Michael Sonstige oth Erscheint auch als Druck-Ausgabe 9781493913923 Erscheint auch als Druck-Ausgabe 9781493913947 Erscheint auch als Druck-Ausgabe 9781493939893 https://doi.org/10.1007/978-1-4939-1393-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Targeted Therapy of Acute Myeloid Leukemia Cancer research Pharmacology Cell biology Microbiology |
| title | Targeted Therapy of Acute Myeloid Leukemia |
| title_auth | Targeted Therapy of Acute Myeloid Leukemia |
| title_exact_search | Targeted Therapy of Acute Myeloid Leukemia |
| title_exact_search_txtP | Targeted Therapy of Acute Myeloid Leukemia |
| title_full | Targeted Therapy of Acute Myeloid Leukemia edited by Michael Andreeff |
| title_fullStr | Targeted Therapy of Acute Myeloid Leukemia edited by Michael Andreeff |
| title_full_unstemmed | Targeted Therapy of Acute Myeloid Leukemia edited by Michael Andreeff |
| title_short | Targeted Therapy of Acute Myeloid Leukemia |
| title_sort | targeted therapy of acute myeloid leukemia |
| topic | Cancer research Pharmacology Cell biology Microbiology |
| topic_facet | Cancer research Pharmacology Cell biology Microbiology |
| url | https://doi.org/10.1007/978-1-4939-1393-0 |
| work_keys_str_mv | AT andreeffmichael targetedtherapyofacutemyeloidleukemia |